Category Archives: Cannabis Legalization

Medipharm Labs Is Looking To Capitalize On B2C In A Major Way Through LABS Cannabis

Medipharm Labs Is Looking To Capitalize On B2C In A Major Way Through LABS Cannabis

Early last week, MediPharm Labs (LABS) (MEDIF) reported a major development as it relates to the cannabis 2.0 market and announced the launch of a product line of family of health and wellness called LABS Cannabis. This represents a major change in direction for the business and we have always been favorable on this possibility for it.

MediPharm expects the first product to launch early in the fourth quarter of 2020 and we are bullish on the potential that is associated with the strategy. The premium product line will target Canada’s recreational cannabis market and will distribute products through government and private retail channels.

In late 2018, MediPharm was granted a Sale License from Health Canada and has a proven track record of success in the cannabis concentrate market. The company works out of a sophisticated GMP certified facility and has a reputation of being a best-in-class operator and a global leader in the manufacturing of premium cannabis products.

We expect the LABS Cannabis portfolio to offer premium cannabis products that meet the standards of the most discerning customers. From a consumer standpoint, we like to compare the cannabis industry to the wine industry in the sense that there is a very high-end consumer. These types of consumers want to buy the best products and do not care as much about the cost.

Although the LABS Cannabis portfolio will predominantly include wellness products that are formulated with cannabidiol (CBD), MediPharm plans to have specialized offerings that could also be formulated with tetrahydrocannabinol (THC) and/or other minor cannabinoids that address potential effects. We expect this vertical to lead to margin expansion for MediPharm in 2021 and are bullish on how the story has evolved.

Last year, EY Canada conducted a survey of approx. 3,000 individuals to better understand the perspective of the average Canadian cannabis consumers. A segment of the survey group was referred to as a Wellness Inquisitor who consume almost daily and spend about $165 each per month on cannabis products. If this analysis was expanded and the percentages were used on the entire Canadian population, there would be 1.1 million Wellness Inquisitors. This segment reported that quality (83%) and intended effects (76%) are the most important purchase criteria and believe that MediPharm could be able to capitalize on this population.

Pursuant to an agreement between StoneBridge Partners LLC and Medipharm Labs we have been hired for a period of 180 days beginning August 18, 2020 and ending March 18, 2020 to publicly disseminate information about (LABS) including on the Website and other media including Facebook and Twitter. We are being paid $6,000 per month (LABS) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero (0) shares of (LABS), which we purchased in the open market. We plan to sell the “ZERO” shares of (LABS) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (LABS) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Mon, 02 Nov 2020 16:08:17 +0000

Subversive Real Estate Acquisition REIT LP Aligns Shareholder Interests and Enhances Transaction with Grant of Rights to Holders of Non-Redeemed Restricted Voting Units

Subversive Real Estate Acquisition REIT LP Aligns Shareholder Interests and Enhances Transaction with Grant of Rights to Holders of Non-Redeemed Restricted Voting Units

Subversive Real Estate Acquisition REIT LP (NEO: SVX.U) (NEO: SVX.RT.U) (OTCBB: SBVRF) today announced that it has agreed to grant an aggregate of up to 24,116,750 million contingent rights to holders of restricted voting units that are not redeemed in connection with the REIT LP’s previously announced qualifying transaction and to holders of Restricted Voting Units that are issued in connection therewith, which Contingent Rights will be issued to holders of record on the day following the closing of the REIT LP’s qualifying transaction.

The Contingent Rights will be distributed to holders of Restricted Voting Units pro rata based on the number of Restricted Voting Units held by such holder.Accordingly, if there are no redemptions of Restricted Voting Units, each holder of record will receive one Contingent Right per Restricted Voting Unit held. To the extent there are redemptions of Restricted Voting Units, each Non-Redeeming Holder will receive more than one Contingent Right per Restricted Voting Unit held, depending upon the quantum of redemptions.

On the automatic exercise of the Contingent Rights, holders will be entitled to receive, for no additional consideration, one limited partnership unit for every five Contingent Rights held, which may be subject to adjustment. The Contingent Rights will automatically be exercised by the holders thereof upon the earlier of (a) the listing of the REIT LP units on a recognized major U.S. exchange, and (b) cannabis production and sale becoming federally legal in the United States . In support of the transaction, and in connection with the issuance of the Contingent Rights, the REIT LP’s founders will forfeit the equivalent of approximately four million Limited Partnerships Units in the form of proportionate voting units with a notional equity value of approximately US$40 million .

Michael Auerbach , Chief Executive Officer at Subversive Capital and Executive Chairman at the REIT LP stated, “The grant of the Contingent Rights shows the commitment of the REIT LP’s founders to the success of its Qualifying Transaction, and provides a significant benefit to investors upon a future U.S. listing or cannabis becoming federally legal in the United States . We continue to believe our diverse portfolio of 15 industrial and retail properties in strategic, high growth cannabis markets, which are leased to leading operators, presents an extremely attractive opportunity for investors as the second publicly traded cannabis REIT,  with a targeted 6.5% initial annualized cash distribution yield, paid monthly, as well as a substantial growth opportunity over time.”

The REIT LP has applied to list the Contingent Rights on the Neo Exchange Inc. under the symbol SVX.RT.C. The listing of the Contingent Rights is subject to the REIT LP fulfilling all of the requirements of the exchange.

The Contingent Rights will not possess any redemption or distribution rights. The Contingent Rights will expire and be worthless if they do not convert upon their terms prior to the 10 th anniversary of the Closing.

No fractional Contingent Rights will be issued. If a holder would be entitled to receive a fractional interest in a Contingent Rights, we will round down to the nearest whole number of Contingent Rights to be issued to such holder. The Contingent Rights will not be distributed if the REIT LP’s qualifying transaction does not close.

For more information, the Company has posted an investor presentation and preliminary long form prospectus to its website at www.subversivecapital.com/reit .

Additionally, the Company held a conference call to discuss the Qualifying Transaction on October 9, 2020 . A webcast replay of the conference call is available on the Company’s website.

About Subversive Real Estate Acquisition REIT LP

Subversive Real Estate Acquisition REIT LP is a limited partnership established under the Limited Partnerships Act ( Ontario ) formed for the purpose of effecting, directly or indirectly, an acquisition of one or more businesses or assets, by way of a merger, amalgamation, arrangement, equity exchange, asset acquisition, equity purchase, reorganization, or any other similar business combination involving the REIT LP that will qualify as its qualifying transaction for the purposes of the rules of the Neo Exchange Inc. (the ” Exchange “) The REIT LP is a special purpose acquisition corporation for the purposes of the rules of the Exchange. The REIT LP’s Restricted Voting Units and Contingent Rights are listed on the Exchange under the symbols “SVX.U” and “SVX.RT.U”, respectively.

Forward-Looking Statements

This press release may contain forward looking information within the meaning of applicable securities legislation, which reflects the REIT LP’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the REIT LP’s control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. The REIT LP does not undertake any obligation to update such forward looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE Subversive Real Estate Acquisition REIT LP

Published at Mon, 19 Oct 2020 12:37:26 +0000

Wildflower Brands’ subsidiary, City Cannabis, completes state of the art buildout of its flagship store

Wildflower Brands’ subsidiary, City Cannabis, completes state of the art buildout of its flagship store

Wildflower Brands Inc . (CSE: SUN ) (CNSX:SUN.CN) ( OTC: WLDFF ) announces that City Cannabis Co, a wholly-owned subsidiary of Wildflower has completed its buildout of their flagship location in the heart of downtown Vancouver on the most popular shopping street, Robson.

With the city of Vancouver’s strict distancing from sensitive use areas and other cannabis store location restrictions, City Cannabis has positioned itself in the most sought after area in Western Canada .

“Every aspect, such as our one-of-a-kind pneumatic tubing product delivery system, has been designed to provide a truly unique experience you won’t get anywhere else”, says Krystian Wetulani, CEO of City Cannabis. “The unique feel and design now match our unrivalled product quality and consistency that the City Cannabis brand has become synonymous for.”

“This build-out was funded from our revenues, and at nearly a million dollars, it speaks to the strength of our business”, says William Maclean, CEO of Wildflower Brands. “This store is the flagship and will be the standard, not only for all of our subsequent stores, but for the industry as a whole.”


Click Image To View Full Size

ABOUT WILDFLOWER BRANDS INC.

Wildflower Brands is a Vancouver-based company developing and designing brands that focus on plant-based health and wellness products. All of our brands work in synergy, toward becoming a global wellness leader.

For more information about Wildflower Brands, visit wildflowerbrands.co . To learn, engage and shop our wellness products visit buywildflower.com .

ABOUT CITY CANNABIS CO.

City Cannabis is a premier cannabis retailer recently acquired by Wildflower Brands and holds three City of Vancouver licenses to sell cannabis and four licenses in the Province of B.C. City Cannabis has been profitabl e operating various dispensaries in Vancouver since Vancouver commenced licensing cannabis retailers.

For more information about City Cannabis, visit citycannabis.co .

Corporate Communications Contact:

Krystian Wetulani, Director & CDO

ir@wildflowerbrands.co

1-604-559-0420

Doug Kerr

communications@wildflower.ca

1-604-315-4400

Canadian Securities Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this press release.

Copyright (c) 2020 TheNewswire – All rights reserved.

Source: TheNewsWire (October 7, 2020 – 9:10 AM EDT)

News by QuoteMedia
www.quotemedia.com

Published at Wed, 07 Oct 2020 14:13:06 +0000

3 Canadian Licensed Producer Updates Investors Need To Know

3 Canadian Licensed Producer Updates Investors Need To Know

During the last quarter, the Canadian cannabis sector has come under the microscope of the investment community and the market is analyzing the long-term viability of several key  Canadian operators.

Over the next year, we expect to see further consolidation in the Canadian cannabis industry. We also expect to see an increase in the number of companies that are filing for bankruptcy and believe that the industry is reaching an inflection point.

Selectivity has never been more important than it is today in the cannabis industry and we tend to prefer companies that meet specific criteria. Today, we want to highlight 3 Canadian Licensed Producers (LPs) that have reported significant developments over the last quarter and believe that these are operators to be aware of.

Will Cannabis Beverages Turn the HEXO Story Around?

Last month, HEXO Corporation (HEXO.TO) (HEXO) made headlines after it reported to have advanced the strategic relationship that it has with Molson Coors (TAP.CN). The companies formed Truss Beverage Co. and introduced 5 cannabis beverage brands to the Canadian cannabis market.

Truss’ cannabis beverage portfolio includes a variety of CBD and THC products that are full of natural flavors and we are favorable on the diversity of the product line. Going forward, Truss plans to rollout one of the widest cannabis beverage portfolios to the Canadian market and we will monitor how the partnership is able to execute on a coast-to-coast growth strategy.

According to a new study from Truss Beverage, 71% of Canadians of legal age cite smoking as the primary barrier to consuming cannabis, with 74% saying the smell of cannabis on their clothing is an issue (based on the Cannabis Culture Report 2020: Cannabis Usage & Attitudes, DIG Insights, May 2020).

During the last year, HEXO has been under substantial pressure and we believe that the relationship with Coors could prove to be the catalyst that the Canadian cannabis producer needed. We believe that the relationship with Molson Coors is a key pillar of the HEXO opportunity and will monitor how it benefits both businesses over the long-term.

Aurora Cannabis: Appoints New CEO after US CBD Acquisition

2020 has been a roller coaster for Aurora Cannabis Inc. (ACB.TO) (ACB) and we believe that analysts are starting to question its ability to survive the current market environment. From the closing of facilities to divesting previously acquired assets, the last twelve months have been challenging for the Canadian cannabis producer.

A few months ago, Aurora Cannabis announced the acquisition of Reliva, a hemp-derived CBD product company in the US. The transaction includes a potential earn-out that is structured to align risk and reward between Aurora shareholders and Reliva management to focus on continued strong operational and financial execution.

When the deal was announced, Aurora Cannabis reported that it expects the transaction to be immediately accretive on an adjusted EBITDA basis and we will monitor how the acquisition supports the growth of the business. We continue to be cautiously optimistic with the CBD market due to the saturation of the industry and hope that Aurora knew what it was doing when it announced the deal.

Following the acquisition, Aurora Cannabis appointed Miguel Martin as CEO and we will monitor how he is able to drive the story forward. With Martin as CEO, Aurora Cannabis plans to execute a tactical growth strategy that is intended to grow Aurora’s leading market share in key profitable Canadian consumer categories, protect and enhance Aurora’s leading market share in Canadian medical cannabis, grow the international medical business, and build leading brands under Reliva in the US CBD market.

We continue to be cautiously optimistic with Aurora Cannabis and will monitor how the management team is able to cut costs and grow revenues. The name of the game for Aurora Cannabis is execution and we will be closely following the story from here.

Canopy Growth: Trying to Increase Market Share

Last year, Canopy Growth Corporation (WEED.TO) (CGC) was considered to be the leading player in the Canadian and in the global cannabis market. A lot has changed in the last year and the company is working to optimize the business through strategic growth projects and cost cutting initiatives.

In 2019, Canopy Growth announced the firing of Bruce Linton as its CEO and Chairman. Following the firing of Bruce, Canopy Growth announced the closure of several cultivation facilities and recorded a $743 million impairment charge in the fourth quarter. These developments represent a major change in strategy for the cannabis producer and we will monitor how it benefits the business over the long-term.

During the last few months, several broker-dealers downgraded and lowered price targets on Canopy Growth and we find this to be of significance. In the most recent quarter, Canopy Growth recorded a $1.3 billion net loss and this number was much higher than what analysts were forecasting.

Although the last few months have been challenging for the Canadian cannabis producer, the business has a bright future. With almost $2 billion of cash on the balance sheet, Canopy Growth is well positioned to survive a prolonged downturn, and this is an opportunity that we will continue to closely monitor.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Mon, 21 Sep 2020 11:44:11 +0000

Rubicon Organics to Commence Trading on the TSX Venture Exchange

Rubicon Organics to Commence Trading on the TSX Venture Exchange

Rubicon Organics Inc. (CSE:ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified, premium cannabis, is pleased to announce that further to its press release dated July 27, 2020, the Company has received final approval to list its common shares and 3,150,000 warrants of the Company on the TSX Venture Exchange (the “TSX-V”).

The common shares and warrants of the Company are expected to be voluntarily delisted from the Canadian Securities Exchange at the close of trading on September 21, 2020 and are expected to commence trading on the TSX-V at the opening of trading on September 22, 2020.  The Company’s common shares will continue to trade under the symbol “ROMJ” and its warrants will continue to trade under the symbol “ROMJ.WT”.

“Rubicon Organics is listing on the TSX-V to increase the liquidity of our common shares and raise our profile in the capital markets. Having recently closed an equity financing during very challenging market conditions, we have secured the balance sheet we require to execute on a very exciting pipeline of milestones which includes ramping production and revenue at our Delta, BC facility, expanding our distribution capabilities and investing in product innovation showcasing our super-premium and organic certified cannabis,” said Jesse McConnell, Chief Executive Officer.

ABOUT RUBICON ORGANICS INC.

Rubicon Organics Inc., through its wholly owned subsidiary Vintages Organic Cannabis Company Inc., is a licensed producer focused on cultivating and selling organic certified, premium cannabis from its flagship 125,000 sq. ft. state-of-the-art hybrid-greenhouse located on a 20-acre property in Delta, BC, Canada. The Company is focused on achieving industry leading profitability through the development of the brand identity Simply Bare™ Organic, that combines the sale of high-margin, premium organic products with low-cost sustainable production. The Company is currently ramping up to production capacity of 11,000 kg per year of organic certified and environmentally sustainable cannabis.

CONTACT INFORMATION

Margaret Brodie
Chief Financial Officer
Phone: +1 (437) 929-1964
Email: ir@rubiconorganics.com

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the Canadian Securities Exchange accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, and statements regarding the Company’s expectations of when its securities will be delisted from the CSE and when trading will commence on the TSX-V; the Company’s belief that listing on the TSX-V will provide it and its shareholders with advantages, including greater visibility and enhanced market access for Canadian and international investors; the Company’s belief that it will gain more exposure through a larger market by listing on the TSX-V; the Company’s intention of achieving industry leading profitability; and the Company’s belief that it will achieve an annual production run rate of approximately 11,000 kg of certified organic, premium and environmentally sustainable cannabis are “forward-looking statements”. Forward-looking information can be identified by the use of words such as “will” or variations of such words or statements that certain actions, events or results “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that its capital needs will be as currently projected. Risks and uncertainties associated with forward looking information in this press release include, among others, information or statements concerning the Company’s expectations of financial resources available to fund operations; Rubicon Organics’ limited operating history and lack of historical profits; obtaining the necessary regulatory approvals; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the Company’s ability to obtain financing at reasonable terms though the sale of equity and/or debt commitments; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; that our current relationships with our suppliers, service providers and other third parties will be maintained; and the impact of the current global health crisis caused by the COVID-19 pandemic. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Although Rubicon Organics has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Rubicon Organics assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

Primary Logo

Published at Fri, 18 Sep 2020 11:05:26 +0000

Namaste Debuts “VendorLink” Cannabis Accessory Marketplace Platform

Namaste Debuts “VendorLink” Cannabis Accessory Marketplace Platform

Namaste Technologies Inc. (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF), a leading platform for cannabis products, accessories and education, announced today the launch of VendorLink, a proprietary marketplace platform for brands and vendors to upload and sell their cannabis accessory products to CannMart customers directly. The first brand to utilize VendorLink is Canada Puffin, a leading Canadian hardware company focused on premium handblown glass and natural maple pipes and accessories.

Namaste Technologies Inc. Logo (CNW Group/Namaste Technologies Inc.)

VendorLink allows brands and vendors to upload their product catalogue directly to CannMart.com, to be displayed alongside CannMart’s own accessory inventory. With an expanding national presence and a strong base of loyal repeat customers, CannMart is in a unique position to leverage its online real estate with like-minded industry partners looking to expand their reach and introduce a true marketplace experience in the cannabis accessory space. Brands and vendors interested in establishing a presence on CannMart.com and accelerating their growth using VendorLink can join the waiting list by visiting https://cannmart.com/sell-on-cannmart.

“Having been first conceived two years ago, we are thrilled to present VendorLink as the answer for cannabis accessory vendors large and small, looking to introduce their products to a fresh, Canada-wide audience through CannMart.com via a marketplace model,” said Meni Morim, CEO of Namaste Technologies. “Our debut partner, Canada Puffin, is the perfect brand to celebrate this launch with, as a dedicated proponent of both cannabis and Canadian culture.”

Determined to raise Canada’s national profile as a leader in the cannabis accessory movement, Canada Puffin is the first leading brand to work with CannMart and establish their own VendorLink marketplace presence.

“Namaste’s VendorLink offers a great way for Canada Puffin to introduce our premium accessories to a new audience of dedicated, cannabis-positive Canadians,” said Dale Falkenstein, CEO of Canada Puffin. “We look forward to expanding our presence through the Namaste network and are excited to be featured within this marketplace amongst some of the most notable brands in the industry.”

Canada Puffin’s glass accessories are thoughtfully designed as art pieces, intended to be proudly displayed. Made with authentic, natural Canadian Maple, each unique piece depicts elements of Canadian heritage and culture throughout.

About Canada Puffin
Canada Puffin is committed to creating an open and inviting culture in the ever changing smoking landscape. Through its unique product designs, quality and presentation, it strives to reshape the perception of cannabis and the community.  For more information please visit: https://canadapuffin.com/

About Namaste Technologies Inc.
Headquartered in Toronto, Canada, Namaste Technologies is a leading online platform for cannabis products, accessories, and responsible education. The Company’s ‘everything cannabis store’, CannMart.com, provides medical customers with a diverse selection of hand-selected products from a multitude of federally-licensed cultivators, all on one convenient site. The Company also distributes licensed and in-house branded cannabis and cannabis derived products to recreational consumers in Canada through a number of provincial government control boards and retailing bodies. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
Cannmart.com

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/namaste-debuts-vendorlink-cannabis-accessory-marketplace-platform-301133743.html

SOURCE Namaste Technologies Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2020/18/c4232.html

Incite Capital Markets, Eric Negraeff / Darren Seed, Meni Morim, CEO, Namaste Technologies Inc., Ph: 604.493.2004, Email: ir@namastetechnologies.comCopyright CNW Group 2020

Published at Fri, 18 Sep 2020 12:04:00 +0000

Medipharm Labs International Growth Strategy Is Starting To Pay Off In A Big Way

Medipharm Labs International Growth Strategy Is Starting To Pay Off In A Big Way

MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) is a global leader in the cannabis extraction market that operates out of a Good Manufacturing Practices (GMP) facility with ISO standard-built clean rooms. The company represents a differentiated opportunity that specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products.

One of the ways that MediPharm has been able to stand out as an industry leader is through the continued delivery of sophisticated cannabinoid formulations in innovative formats with pharmaceutical level quality standards. The company provides a variety of services, depending on customer needs (i.e. formulation, sensory testing, processing, packaging, labelling, and distribution of cannabis extracts and advanced cannabinoid-based products) and we are favorable on how the story has advanced so far this year.

Through its wholesale and white label platforms, MediPharm has been capitalizing on the domestic and international cannabis oil market and has a leading position in this vertical. A few months ago, the company announced its first commercial export order to Australia, which recently started generating revenue, and completed the commercialization of its Australian extraction facility.

We believe that MediPharm is an opportunity that has been flying under the radar and is trading for a discount when compared to its peers. By gaining a first mover advantage in strategic international markets, MediPharm is positioning itself for long-term growth and we believe that the market discounts the growth potential that is associated with it.

Announces a Milestone with Avicanna

Last month, MediPharm Labs reported a major milestone and announced the completion of the production of a new product format, sublingual sprays, as part of its multi-faceted strategic pharmaceutical manufacturing agreement with Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a leading biopharmaceutical company.

In the near future, the sprays will be available to Canadian medical patients through the Medical Cannabis by Shoppers online healthcare platform. The sprays will be marketed under Avicanna’s RHO Phyto™ medical brand and we will monitor how the product line generates traction with medical patients. The sprays are an attractive option for medical patients since they are optimized for increased absorption and faster onset when compared to basic MCT (medium-chain triglyceride) sublingual sprays.

One of the reasons we are favorable on the new product format is related to the amount of time it takes to feel the effects. There is a large portion of medical and recreational customers that want to consume cannabis in ways that are healthier and more discreet than smoking (i.e. vaping and consumables). The sprays meet these specific criteria and are placed under the tongue to provide rapid absorption into the bloodstream.

MediPharm stands out as a leader in the Canadian cannabis oil market and was selected by Avicanna due to its state-of-the-art GMP extraction and processing facility and its pharmaceutical-quality production capabilities. Avicanna is executing on a strategy to bring new and innovative and sustainable plant-derived cannabinoid-based products to market and expect MediPharm to be a beneficiary of this.

The relationship between the companies is designed to provide patients and the medical community with advanced product offerings that are backed by science, data and world-class quality standards. Avicanna has an attractive pipeline of formulations that it has developed over the past four years in collaboration with leading Canadian research institutions.

A few months ago, the companies entered into a three-year, multi-faceted agreement that involves production, domestic and international distribution, and intellectual property licensing. The spray product is the second set of products to be developed by MediPharm and we are favorable on the amount of time it takes MediPharm’s technical team to bring a product to market. The spray product took MediPharm one-month to bring to market and we believe that this is a testament to the strength of the team and the amount of human capital that is on it.

Under the manufacturing segment of the agreement with Avicanna, MediPharm Labs uses its specialized capabilities to produce Avicanna’s advanced RHO Phyto™ medical cannabis products and Pura Earth™ dermacosmetic topicals. The first product that was produced as part of the relationship was Rho Phyto’s Blood Orange flavoured Micro Drops, in both high CBD and medium CBD formula made from full spectrum cannabis distillate.

Going forward, the companies plan to bring additional products to market and we are favorable on the track record of success so far. Additional product formats such as topicals, capsules and transdermal patches, are being finalized for production under the contract manufacturing agreement and we expect to see additional product brought to market in the near future.

In late 2019, Health Canada approved the sale of cannabis derivative products like edibles, drinkables, vape pens, concentrates, sublinguals, topicals, tinctures, salves, and more. This represented a major transformation of the Canadian market and is referred to as cannabis 2.0.

We believe that MediPharm is well positioned to be a beneficiary of the cannabis 2.0 market and expect it to report strong growth from this vertical on a going forward basis. The completion of the second product with Avicanna highlights how the Canadian cannabis market has changed and how MediPharm is increasing market share in the contract manufacturing space.

One of the ways that the cannabis 2.0 market has impacted the entire Canadian industry is through the formation of a new consumer segment that is not price sensitive and will pay a premium price for quality products. We like to compare this group of consumers to the wine industry which has a large segment of wine connoisseurs and who pay a massive premium for certain brands.

Through contract manufacturing and white label agreements with brand leaders, as well as its growing portfolio of pharmaceutical quality products that are produced from its GMP-certified facilities in Canada and Australia, MediPharm is well positioned to capitalize on the changing landscape of the domestic and international cannabis market.

By the end of the second quarter, MediPharm Labs had 60 concentrate-based product SKUs in production for medical, wellness and recreational brands. Some of the products that are in the portfolio are high-potency formulated oils, vape cartridges, topicals and sublingual sprays. We are favorable on the amount of MediPharm owned or produced products that are on the market and expect this trend to become more significant in the back half of the year.

MediPharm continues to enhance its capabilities in product innovation and flexible manufacturing and we are favorable on how it continues to focus on improving the process. The business is supported by a distinguished team of researchers and production professionals that have decades of pharmaceutical experience and this is an attractive aspect of the story. The company is systematically executing on a multi-faceted growth strategy as a differentiated, international pharmaceutical company and partner to leading cannabis brands.

Pursuant to an agreement between StoneBridge Partners LLC and Medipharm Labs we have been hired for a period of 180 days beginning August 18, 2020 and ending March 18, 2020 to publicly disseminate information about (LABS) including on the Website and other media including Facebook and Twitter. We are being paid $6,000 per month (LABS) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero (0) shares of (LABS), which we purchased in the open market. We plan to sell the “ZERO” shares of (LABS) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (LABS) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share

Share - Facebook


Share - Twitter

Published at Tue, 15 Sep 2020 11:35:44 +0000

Auxly Closes $2 Million Tranche of Financing

Auxly Closes $2 Million Tranche of Financing

Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (“Auxly” or the “Company”) has issued an additional $2 million worth of unsecured convertible debentures (the “Tranche”) under its $25 million unsecured convertible debenture standby facility with an institutional investor (the “Investor”) as previously announced on April 28, 2020 (the “Original Offering”).

Under the Tranche, the convertible debentures issued to the Investor have a conversion price of $0.18 per common share of the Company (each a “Common Share”), and the Investor received warrants to purchase 6,111,111 Common Shares until September 8, 2022 at an exercise price of $0.216 per Common Share. Each convertible debenture will mature on September 8, 2022 and will bear guaranteed interest from the date of issue at 7.5% per annum, payable semi-annually on June 30 and December 31 of each year and has the same terms and conditions as described in the Original Offering and the transaction documents filed on the Company’s SEDAR profile.

In connection with the completion of the Tranche, the Company has agreed to indemnify (the “Indemnity”) certain of its directors and officers for any and all losses not otherwise recoverable from the collateral provided by the Investor for the Common Shares provided by such directors and officers to the Investor pursuant to the terms of the investment agreement. The Indemnity may constitute a related party transaction under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“), but is otherwise exempt from the formal valuation and minority approval requirements of MI 61-101. The Indemnity has been approved by the independent directors of the Company. No special committee was established in connection with the Original Offering, the completion of the Tranche or the granting of the Indemnity, and no materially contrary view or abstention was expressed or made by any director of the Company in relation thereto. Further details will be included in a material change report that will be filed by the Company in connection with the completion of the Tranche. The Company did not file the material change report more than 21 days before the expected closing date of the Tranche as the details of the Tranche and the terms of the Indemnity were not settled until shortly prior to the closing of the Tranche, and the Company wished to complete the Tranche on an expedited basis for sound business reasons.

All securities issued by the Company under the Tranche are subject to a statutory four-month hold period in accordance with applicable securities legislation and final approval of the TSX Venture Exchange.

AltaCorp Capital Inc. is acting as exclusive agent on the Tranche.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any of the securities referenced herein in the United States. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

ON BEHALF OF THE BOARD

“Hugo Alves” CEO

About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF)

Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries has secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading product research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:
For investor enquiries please contact our Investor Relations Team:
Email: IR@auxly.com
Phone: 1.833.695.2414

Media Enquiries (only): 
For media enquiries or to set up an interview please contact:
Email: press@auxly.com

Notice Regarding Forward Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information in this press release includes, but is not limited to: the expected use of proceeds of the offering by the Company; obtaining the necessary regulatory approval for the offering; political change; future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting Auxly in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information included in this release including, but not limited to: whether the Company can complete the offering on the anticipated terms and timeline; the ability to obtain regulatory approval of the offering on the proposed terms and timeline; and general economic, financial market, legislative, regulatory, competitive and political conditions in which Auxly operates will remain the same. Additional risk factors are disclosed in the annual information form of Auxly for the financial year ended December 31, 2019 dated May 13, 2020.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on Auxly’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. The purpose of forward-looking information is to provide the reader with a description of management’s expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this release.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Primary Logo

Published at Wed, 09 Sep 2020 11:34:39 +0000

Avicanna Advances its Supply Chain Business and Announces Filing of Amended Interim Financial Statements

Avicanna Advances its Supply Chain Business and Announces Filing of Amended Interim Financial Statements

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces that through its majority owned subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH“), the Company has completed exports of CBD water soluble formula into the United States and CBD-based cosmetics into the United Kingdom. The Company is also pleased to announce that the Colombian Ministry of Health has granted SMGH a commercial and industrial fabrication quota to produce psychoactive THC derivatives.

Avicanna Inc. Logo (CNW Group/Avicanna Inc.)

The Company also announces that it has amended and refiled its interim financial statements for the period ended June 30, 2020 (the “Interim Financial Statements”) which amend the Company’s interim financial statements for the same period originally filed on SEDAR on August 14, 2020. At the request of the Ontario Securities Commission, the Interim Financial Statements have been updated to include comparative financial information for the corresponding interim period in the immediately preceding financial year as such information was inadvertently omitted in the initial filing. The changes are for presentation purposes and no figures have been restated. The Company has updated the Statement of Changes in Equity to include the immediately preceding financial year June 30, 2019 balances as required by Section 4.3(2)(b) of National Instrument 51-102 – Continuous Disclosure Obligations.

The export and sale of the commercial lot of isolated CBD water soluble formula into the United States was completed in parallel with an export of CBD-based cosmetics into the United Kingdom. The cultivation, extraction and purification of these products were all completed through Avicanna’s vertical integration at SMGH and validate the Company’s innovation and leadership in natural rare cannabinoid production. The CBD water soluble formula is part of the Aureus™ product portfolio that now includes feminized seeds and advanced formulations as well as CBD, CBG and THC API products. The CBD-based cosmetics were manufactured using CBD produced by SMGH and formulas developed by Avicanna.

The Colombian Ministry of Health granted SMGH a supplementary fabrication quota to receive 1.4 tons of dry flower and transform them into approximately 150 kg of psychoactive derivatives which will be used for commercial exports.

To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About Avicanna

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at info@avicanna.com.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to complete additional exports of  CBD water soluble formula to the United States, the ability of the Company to complete additional exports of CBD-based cosmetics in to the United Kingdom, the ability of the Company to continue manufacturing CBD-based cosmetics using CBD produced by SMGH, the ability of SMGH to receive 1.4 tons of dry flower for the purposes of extracting psychoactive derivatives, and the ability of SMGH to produce 150 kg of psychoactive derivatives. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Avicanna Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2020/04/c5603.html

Published at Fri, 04 Sep 2020 12:10:44 +0000

World High Life Investment Strategy Update

World High Life Investment Strategy Update

World High Life Plc (AQSE:LIFE)(OTCQB:WRHLF) is pleased to announce that, in accordance with the Company’s investment strategy, and building upon momentum from its wholly owned subsidiary, London based Love Hemp Limited (“Love Hemp”), the Company is now actively considering investment targets in the medicinal cannabis space, including new technologies and synthetic cannabinoids with potential for wide applications in multiple jurisdictions.

“There are compelling opportunities to achieve our mandate, improving quality of life and wellness through innovations in medicinal cannabis, synthetic pharmaceutical derivatives, CBD and Hemp, with a number of investment opportunities that our team is actively pursuing,” noted Mr. David Stadnyk, World High Life CEO.

World High Life Investment Strategy Highlights

  • Building on Love Hemp’s continued growth, World High Life leadership is seeking new strategic investments in the medicinal cannabis sector, including pharmaceutical applications
  • Potential areas of interest include new technologies, synthetic cannabinoids, CBD, and Hemp, where they can be applied to scale globally
  • Within this scope, the Company intends to invest in and scale innovative, early stage, uses of cannabinoids, which have existing approvals in place to benefit patients/users

“The Love Hemp team is doing terrific work, advancing its business model under difficult circumstances, due to COVID-19, and growing on many fronts. That momentum has allowed our World High Life team to become more active on the investment side of our business as we see tremendous opportunities, especially in the cannabinoid pharmaceutical space,” added Mr. Stadnyk.

For further information please contact:

David Stadnyk
Founder & CEO
North America: 1 (236) 521-7211
North America toll-free: 1 (888) 616-WRHLF (9745)
+44 (0) 7926 397 675

info@worldhighlife.uk

AQSE Corporate Adviser
Mark Anwyl/Allie Feuerlein
Peterhouse Capital Limited
+44 (0) 20 7469 0930
ma@peterhousecap.com
af@peterhousecap.com

Financial PR
Camilla Horsfall/Megan Ray
Blytheweigh
+44 (0) 20 7138 3224
Camilla.horsfall@blytheweigh.com
Megan.Ray@blytheweigh.com

For more information on World High Life please visit: www.worldhighlife.uk

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

Cautionary Note Regarding Forward Looking Information

We seek safe harbour. Some statements contained in this news release are “forward looking information” within the meaning of securities laws. Forward looking information include, but are not limited to, statements regarding the use of proceeds of the non-brokered private placement and payment of the debt settlements. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes” or variations of such words and phrases (including negative or grammatical variations) or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual results to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management’s current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. We do not undertake to update any estimate at any particular time or in response to any particular event, except as required by law.

SOURCE: World High Life Plc

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Fri, 04 Sep 2020 12:14:01 +0000